Trial Profile
Fulvestrant in Hormone-refractory prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 03 Jul 2012 Actual patient number 10 added as reported by ClinicalTrials.gov.
- 19 Jan 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.